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Abstract 
 
Because of the lack of curative approaches for most patients with malignant brain tumors, 
supportive therapy which aims at maintaining quality of life and functional independence has 
a central role in the treatment of many patients. Here, steroids play a central role: they are 
commonly used to treat tumor-associated edema and their administration is typically 
associated with rapid symptom relief such as the resolution of headaches. Beside their anti-
edema activity, corticosteroids are characterized by their potent anti-lymphoma properties and 
their effects against acute or delayed emesis caused by systemic chemotherapy in cancer 
patients. Accordingly, steroids are among the most frequently used drugs in oncology, not 
only in patients with brain tumors. These desirable properties of steroids are counterbalanced 
by cardiovascular, muscular and psychiatric side effects. On the cellular level, corticosteroids 
exert various effects which translate into the desired clinical activity but also evoke significant 
toxicity which may outweigh the beneficial effects. The mode of action and the limitations of 
steroid treatment are summarized in this review article. Interactions between steroids and 
other drugs must be considered. A particular challenge to the ongoing use of glucocorticoids 
is that fact that newer therapeutic approaches are being introduced in neuro-oncology for 
which concomitant steroids are likely to be contraindicated. These include the emergence of 
various immunotherapeutic approaches including vaccination strategies and treatment with 
immune checkpoint inhibitors. Since the administration of steroids may interfere with the 
activity of these novel therapies, an even more critical evaluation of their use will be required.  
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Background 
 
Corticosteroids are a class of biological mediators produced within the adrenal gland and 
synthesized from cholesterol. They are involved in the regulation of various processes such as 
metabolism, electrolyte regulation, inflammation and stress responses. Based on their major 
effects they are divided into different groups including glucocorticoids and 
mineralocorticoids. Cortisol is the most prominent physiological mediator exerting 
glucocorticoid effects in humans, aldosterone is the hormone with the strongest 
mineralocorticoid activity. Chemical modifications of the naturally occurring steroid 
hormones resulted in the generation of numerous synthetic corticosteroids within the last 
decades. Since then, these drugs have played a prominent role in the treatment of various 
pathological conditions and diseases. The gluco- and mineralocorticoid activity of these 
synthetic drugs varies significantly. Accordingly, choosing the appropriate compound requires 
anticipation of the desired effect but also careful consideration of potential side effects.  
As outlined below in more detail, steroids are administered to brain tumor patients mainly to 
(i) reduce the tumor-surrounding edema and thereby the mass effect in the brain, (ii) target 
lymphomas in the CNS and (iii) prevent or treat chemotherapy-induced nausea and vomiting. 
These effects are mediated by the glucocorticoid activity of steroids. The glucocorticoid and 
mineralocorticoid potency of some frequently administered corticosteroids are summarized in 
Table 1. The available compounds differ significantly in their duration of action. Because of 
its long half-life, which allows for administration of a single daily dose, dexamethasone has 
been the favourite drug for most indications. Furthermore, its strong glucocorticoid potency 
associated with virtually absent mineralocorticoid effects reduces the risk of electrolyte 
imbalances.  
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Mode of action 
 
Glucocorticoids interact with the glucocorticoid receptor (GR) which is encoded by a gene 
located on chromosome 5 1. The expression of the GR gene is under the control of at least 3 
promoters which allows for tissue-specific GR expression 2. Because of alternative splicing as 
well as post-transcriptional and post-translational modifications, multiple GR isoforms exist 3. 
The GR contains DNA-binding and ligand-binding domains 4. It binds to several other 
proteins including heat shock protein 90 which interacts with the ligand-binding domain and 
thereby maintains the receptor in an inactive state 5. Activation of the GR requires binding of 
a ligand which results in GR hyperphosphorylation and translation into the nucleus. The 
transcriptional effects of the GR are mediated through interaction of its DNA-binding domain 
with glucocorticoid-responsive elements (GRE) which are specific DNA sequences. The 
transcriptional activity of the GR is conferred by additional co-activators which comprise a 
group of proteins that induce conformational changes in the GR which promote GR-mediated 
transcriptional activation 6. Still, it has not been fully understood how a receptor such as the 
GR can mediate a variety of different effects on the cellular level. Ligand binding to the GR 
can result in a direct induction or repression of target gene expression. Furthermore, steroid-
mediated induction of transcription factor expression controls numerous additional genes 
which contributes in an indirect manner to the multitude of steroid-exerted effects 7. 
The clinical application of synthetic steroids, e.g. their use for the treatment of brain tumor 
edema or their anti-lymphoma activity, is frequently limited by their diminishing effect over 
time. The underlying mechanisms which preclude durable responses to steroids have been 
largely unknown. On the cellular level, the administration of drugs which act as agonists on 
the GR induces a down-regulation of GR expression 8,9, an effect which is mediated by 
reduced GR transcription, decreased half-life of GR mRNA and reduced stability of the GR 
protein 10,11. Together with other cellular processes, these mechanisms may contribute to the 
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development of resistance to steroid treatment in different conditions. Steroids are finally 
metabolized in the liver in a cytochrome P450-dependent manner 12. Combined administration 
of drugs which act as P450 inducers such as the anticonvulsant phenytoin, which is still 
commonly used, may therefore alter the turnover of glucocorticoids and reduce their 
bioavailability 13,14. 
 
Indications for the use of steroids 
 
Anti-edema activity  
The striking anti-edema effects of steroids have been recognized several decades ago 15. Since 
then, glucocorticoids have been used for various conditions where a reduction of the 
intracranial pressure due to a peritumoral fluid collection must be achieved. Accordingly, 
steroids are commonly applied in a prophylactic manner perioperatively, during radiation 
therapy and whenever rapid relief from clinical symptoms due to mass effect in the brain is 
required 16,17. Steroids modulate the permeability of the blood brain barrier (BBB) which is 
frequently compromised in brain tumors because both benign and malignant brain tumors 
secrete various cytokines such as vascular endothelial growth factor (VEGF) which act on 
endothelial cells located within or around the tumor. Although edema is most commonly 
found in patients with malignant lesions such as high-grade gliomas or metastases, it can also 
increase the mass effect of benign tumors such as meningiomas 18,19. The effects of 
glucocorticoids on the BBB are mediated through various genes and molecules including 
claudins, occludin, zona occludens (ZO)-1 and vascular endothelial (VE)-cadherin which 
influence endothelial permeability. Steroid administration decreases the permeability of the 
BBB and limit the extravasation of fluid 20,21. Similar to other steroid effects, the anti-edema 
activity is temporary. Even in the context of scenarios with ongoing anti-edema benefits, 
  NOP-D-14-00036R1 
6 
 
sustained administration of steroids can impair quality of life because of severe side effects 
(see below).  
 
Treatment of lymphomatous neoplasms 
Primary CNS lymphomas (PCNSL) or secondary lymphomatous neoplasms of the brain 
typically respond quickly upon administration of steroids which can induce cell cycle arrest 
and cell death, mostly apoptosis in a p38 mitogen-activated protein kinase (MAPK)-
dependent manner, in B and T cells 17,22,23. Accordingly, various treatment regimens for 
lymphomas comprise steroids, at least in the beginning of the treatment when rapid effects are 
required. However, steroid effects against lymphomas are transient and the tumor recurs in 
virtually all patients unless a chemotherapeutic regimen or irradiation are applied 24. When a 
lymphoma is suspected, the administration of steroids should be avoided to allow for a 
histopathological confirmation of the diagnosis. Still, even in patients who have already been 
exposed to steroids, the diagnosis may be established successfully 25. Furthermore, rapid 
clinical and radiographic responses to steroid administration are not restricted to lymphomas 
but can also be observed in patients suffering from inflammatory conditions. The situation is 
different in tumor entities other than lymphomas. There is no clinical evidence that steroids 
inhibit the growth of gliomas or metastases in human patients. However, data from preclinical 
studies suggest that the proliferation of some glioma cells is reduced upon exposure to 
dexamethasone 26. This is at odds with other reports which claim that steroids have no effect 
or even stimulate the growth of glioma cells 27,28. Furthermore, there are concerns which are 
largely based on preclinical findings, that the administration of glucocorticoids renders tumor 
cells resistant to chemotherapy 29-31. It remains to be determined whether steroid intake truly 
interferes with the efficacy of chemotherapy in human patients in vivo. However, because of 
this concern, steroid administration in cancer patients should always be critically evaluated.  
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Anti-emetic properties  
Cancer patients receiving systemic chemotherapy are frequently affected by severe nausea 
and vomiting. Chemotherapy-induced nausea and vomiting (CINV) can severely impair 
quality of life and induce further complications such as dehydration and electrolyte 
disturbances. Various drugs including the widely used 5-HT3 receptor antagonists and the 
neurokinin (NK)-1 receptor antagonist aprepitant are available for the prophylaxis and 
treatment of CINV. Corticosteroids such as methylprednisolone and dexamethasone have also 
been used as antiemetic agents for decades 32. Similar to other steroid-mediated effects, the 
receptors and pathways which contribute to these effects have only partially been understood. 
Reduced release of 5-HT3 from blood cells upon administration of steroids as well as direct 
effects on cellular 5-HT3 receptor expression have been suggested as important factors 33,34. 
Furthermore, preclinical data point to a direct effect of corticosteroids in the medulla 
oblongata 35. Steroids are administered either alone or in combination with other drugs. The 
combination of a 5-HT3 receptor antagonist, aprepitant, and dexamethasone has been 
recommended for the prophylaxis of patients treated with moderately or highly emetogenic 
chemotherapy and therefore at high risk of developing CINV 36. Recent data from a 
randomized double-blind study indicate that dexamethasone and aprepitant have similar 
activity in preventing emesis in breast cancer patients receiving a chemotherapy regimen 
containing anthracyclines plus cyclophosphamide 37. Furthermore, there was no significant 
difference in the toxicity profile of the 2 antiemetic regimens used in this trial. Accordingly, 
the value of steroids in the prophylaxis and treatment of CINV remains undisputed and their 
use as single agents may be sufficient in some patients. 
 
Dosing and tapering 
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The vast majority of patients suffering from brain tumors will receive steroids at some point 
in time during the course of their disease 38. Although various synthetic glucocorticoids are 
available, dexamethasone is by far the most frequently used compound, most likely because 
of its properties described above 39. In sharp contrast to the widespread use of glucocorticoids 
in brain cancer patients, there is hardly any evidence from clinical trials guiding choice of 
optimal dose, duration of treatment and tapering schemes. A randomized trial assessed the 
activity of 8 mg dexamethasone versus 16 mg dexamethasone or 4 mg versus 16 mg in 
patients with brain metastases. A similar improvement of the Karnofsky performance status 
(KPS) was observed in all groups. However, side effects were significantly more frequent in 
patients treated with 16 mg dexamethasone per day 40. Whether the dose of glucocorticoids 
should be based on bodyweight or body surface has not been examined either. Furthermore, it 
remains unclear whether elderly patients should receive lower doses than younger patients 
because of an increased risk of side effects and potentially less susceptibility to the 
development of severely increased intracranial pressure. Finally, it remains doubtful whether 
doses higher than 16 mg dexamethasone per day provide additional beneficial effect 41. 
Attempts to define a standard regimen for steroid application have largely failed which means 
that the dose must be adapted to each patient's individual needs 38. Not surprisingly, 
considerable variations in the administration and prescribing practice of steroids have been 
observed 42. Because of steroid-associated toxicity, tapering should be considered as soon as 
clinically acceptable 43. Although reliable data are lacking, it must be assumed that many 
patients receive steroids too long and at a higher dose than necessary 42,44. Steroids can be 
stopped quickly in patients who were taking them for a short period of time, that is, typically 
no longer than 10-14 days. In contrast, prolonged administration for weeks or months requires 
careful tapering over a longer period of time to avoid clinical deterioration because of 
manifest hypocortisolism due to suppression of adrenal function. To exclude the latter, basal 
cortisol levels in the morning may be determined at the end of tapering before the 
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administration is stopped. Patients with insufficient cortisol levels can benefit from 
substitution with hydrocortisone, typically administered in 2 doses in the morning and at noon 
to mimic the physiological secretion of the hormone. In the absence of particular high cortisol 
needs, 20 mg in the morning and 10 mg at noon or early afternoon are sufficient for most 
patients 45. 
 
Side effects and toxicity 
 
Depending on the type and the dose of the administered steroid, side effects can occur in 
different ranges of severity. While some of these undesired effects only develop over time, 
others can manifest within days of the first steroid intake. Most of the symptoms are 
manageable; still, some side effects can be fatal when not recognized.  
One of the most common side effects of steroid exposure is arterial hypertension, occurring in 
at least 20% of patients treated with steroids in a dose-dependent manner 46. This increase in 
systolic blood pressure is usually reversible, and cessation of steroid intake usually normalizes 
blood pressure again. If stopping medication is not an option in the context of the disease, 
symptomatic treatment of hypertension must be established, preferentially with diuretics, as 
hypervolemia induced by steroids is a main cause of hypertension in these patients. 
Another relevant side effect of steroid use is the negative impact on the immune system, 
leading to a higher susceptibility to fungal infections, such as candidiasis and pneumocystis 
jirovecii pneumonia (PJP) 47. In high-risk patients with an impaired immune system, such as 
patients after organ transplantation or patients undergoing chemo- or radiotherapy, 
prophylactic treatment for PJP involving trimethoprim-sulfamethoxazole should be evaluated 
if prolonged steroid exposure is deemed necessary 48.  
Side effects that occur mainly in the long-term course of steroid exposure, but should be 
considered early to avoid morbidity, are, among others, osteoporosis and steroid-induced 
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diabetes. Glucocorticoid-induced osteoporosis is the most common form of iatrogenic 
osteoporosis, and may occur in up to 50% of steroid-treated patients 49,50. It involves an 
increased risk in fractures with more than 5-fold increased risks of hip or vertebral fractures 
51,52, which are associated with higher morbidity and mortality. The use of bisphosphonates 
should be evaluated, and vitamin D and calcium should be supplemented at doses of 800 IU 
and 800-1200 mg per day in such patients 53. In brain tumor patients requiring steroids and 
antiepileptic medication caution needs to be taken since drugs such as valproic acid or 
phenytoin may promote osteoporosis, too 54-56. Replacement of these agents with 
anticonvulsants with a more suitable toxicity profile should be considered. 
Diabetes occurs in up to 50% of steroid-treated patients, and is the most common form of 
drug-induced diabetes mellitus 57. Accordingly, blood sugar levels should be determined 
regularly in patients taking steroids, especially when diabetes preexists. Management of 
steroid-induced diabetes does not differ from that of regular type-2 diabetes, and patients with 
repeatedly pathological blood sugar levels should be treated adequately to prevent long-term 
complications, including cardiovascular and renal damage. 
Steroid-induced myopathy has been described in up to 60% of patients taking steroids, caused 
by decreased protein synthesis and induction of muscle protein catabolism 58. Two distinct 
types of steroid-induced myopathy are described: the less common acute form, a generalised 
myopathy partially associated with rhabdomyolysis, occurring within days after the onset of 
steroid treatment and often associated with high doses of steroids 59,60; and the classic form,  a 
chronic myopathy characterized by proximal muscle weakness, that develops over a longer 
time course after prolonged steroid administration 58,61. Myopathy may have even more 
devastating impacts on patients who already have a motor deficit or balance issues relating to 
their tumor. It has repeatedly been claimed that myopathy occurs more frequently when 
fluorinated steroids are administered 62-64. However, compelling evidence from clinical trials 
comparing fluorinated and non-fluorinated steroids is lacking. Accordingly, due to its long 
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half-life, low mineralocorticoid effects and high glucocorticoid potency, dexamethasone, a 
fluorinated drug, remains the first choice of steroid in brain tumor patients. Recovery from 
myopathy after dose reduction or tapering may take months, and physical therapy is 
recommended to attenuate the symptoms 65.  
Psychiatric effects of steroids have been described to occur in up to 60% of patients 66,67, 
throughout the treatment period, with early symptoms starting within 2 weeks and being most 
often dose-dependent, such as insomnia, emotional lability, hypomanic and manic episodes, 
and some in the later course, such as depression 68,69. These symptoms tend to resolve after 
cessation of steroid treatment. Meanwhile, neuroleptic drugs, e.g. olanzapine, may be required 
to ameliorate some of these behavioural sequelae. Finally, steroid intake is associated with an 
increase in cataracts and the rare occurrence of avascular bone, e.g., hip necrosis. A summary 
of the most relevant steroid-associated side effects as well as potential prophylactic measures 
and therapies is provided in Table 2. 
 
Steroids and immunotherapy 
 
Immunotherapy has gained increasing interest in neurooncology within the last years because 
of the availability of novel agents which are successfully used or currently evaluated in late-
stage clinical development in other tumor entities. The emergence of various 
immunotherapeutic approaches poses a particular challenge for the use of steroids because of 
their well-known immunosuppressive effects. Steroid-induced lymphopenia increases the risk 
for opportunistic infections (see above) but may also limit therapeutic approaches which aim 
at activating the immune system and boost anti-tumor immune responses.  
One of these novel immunotherapeutic agents, that is, ipilimumab, targets cytotoxic T 
lymphocyte antigen (CTLA)-4 and interferes with the inhibition of T cell function which 
subsequently translates into enhanced anti-tumor activity. While the drug has already been 
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registered for the treatment of advanced melanoma 70, current efforts aim at defining the 
potential activity of ipilimumab in patients with malignant gliomas. Similarly, targeting of the 
immune cell receptor programmed cell death (PD)-1 or its ligand PD-L1 is currently in 
advanced clinical development 71 and clinical trials combining ipilimumab with the anti-PD-1 
antibody nivolumab are currently ongoing in patients with glioblastoma 72. 
Another immunotherapeutic concept, vaccination, has also progressed within the last years 73. 
Again, steroids may interfere with the boosting of an immune response and therefore be 
counterproductive in patients who are treated with a vaccine. Accordingly, several vaccination 
trials restrict the use of steroids at the time of enrolment to select only patients with a suitable 
immunological “configuration”. 
 
Steroid-sparing drugs 
 
Because of the limited activity of steroids and, even more importantly, the side effects 
associated with their administration, steroid-sparing drugs may be very welcome. However, 
convincing alternatives are hardly available. Bevacizumab, which is a VEGF neutralizing 
antibody, has strong anti-edema activity in the brain 74. However, approval for this indication 
is lacking, and cost is a limiting factor at present. The administration of corticorelin acetate, a 
synthetic analog of human corticotropin-releasing factor (hCRF), to brain tumor patients 
allowed for a higher maximal reduction of the dexamethasone dose compared to control-
treated patients in a randomized trial. Furthermore, patients in the corticorelin acetate group 
were less likely affected by myopathy and cushingoid appearance 75. Drugs with uncertain 
effects on the edema surrounding brain tumors include boswellic acids, cyclooxygenase 
(COX)-2 inhibitors and angiotensin-II inhibitors (reviewed in 76). 
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Conclusion and outlook 
 
The introduction of steroids 60 years ago was a milestone in the treatment of brain tumor 
patients. Their rapid effect on the tumor-associated edema makes them indispensable even all 
these decades after their first administration, and steroids remain a mainstay in the 
management of brain tumors. Despite their widespread use, hardly any data from larger 
clinical studies exist which precludes definite answers to important questions including the 
choice of the most appropriate synthetic drug, the most effective dose and the optimal time-
point for tapering. Chronic administration of steroids can be associated with severe side 
effects which must be considered in any patients with regard to quality of life and functional 
autonomy. Steroid independence should be incorporated as exploratory endpoints in future 
trials in brain tumor patients as already done in the AVAGLIO trial 77. A better understanding 
of the cellular mechanisms mediating the clinical activity of corticosteroids may help to 
design novel compounds which selectively confer the urgently needed beneficial effects but 
are no longer associated with detrimental toxicity. In parallel, intense research is needed to 
find novel strategies which allow for a substitution of steroids by other compounds. The 
ongoing development and clinical assessment of corticorelin acetate could be a first step 
towards a reduction of steroids doses and associated side effects . However, a final evaluation 
of this drug is pending and data from additional trials need to be awaited. 
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Table 1. Pharmacological properties of cortisol and synthetic glucocorticoids 
 
 
 Biological 
half-life 
Mineralocorticoid 
potency 
Glucocorticoid 
potency 
Recommended 
daily dose (range) 
Cortisol 
equivalent 
Cushing 
threshold  
Cortisol 
(known as hydrocortisone 
when used therapeutically) 
8-12 h 1 1 - 
(hydrocortisone: 20-
30 mg) 
1 30 
Cortisone 8-12 h 0.8 0.8 - 1.25 40 
Prednisone 12-36 h 0.6 4 5-60 mg 0.25 7.5 
Methylprednisolone 12-36 h - 5 500-1000 mg 0.2 6 
Dexamethasone > 48 h - 30 2-24 mg 0.04 1.5 
Budesonide n.a. n.a. > 30 400-1600 mg n.a. n.a. 
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Table 2. Steroid-associated side effects 
 
Side effects Frequency1 Symptoms Prophylaxis / Treatment 
Cushing’s syndrome 
 
 Moon face 
Hyperglycemia 
Hypertension 
Striae 
P: stay below Cushing threshold (see Table 1) 
 
T: tapering steroid dose below Cushing threshold 
Osteoporosis 
 
Up to 50% Pain 
Fractures 
 
P: short treatment periods 
 
T: Calcium and Vitamin D supplement, bisphosphonates 
Myopathy 
 
Up to 60% Muscle weakness P: stay below 10mg/d prednisone (equivalent) 
 
T: switch from fluorinated to non-fluorinated steroids 
    physical therapy 
Steroid-induced diabetes 
 
Up to 50% Cardiovascular alterations 
Renal failure 
Visual impairment 
P: regular blood sugar samples for early diagnosis 
 
T: diabetes mellitus type 2 therapy regimen    
    (including insulin if necessary) 
Thrombembolic events 
 
3-fold 
increased 
compared to 
untreated 78,79  
Deep venous thrombosis 
Pulmonary embolism 
Stroke 
P: compression hosiery, low-dose heparin, mobilisation 
 
T: oral anticoagulants or heparin in therapeutic doses 
Immunosuppression 
 
30-100% Opportunistic infections 
Wound healing problems 
Ulcerations 
P: regular white blood count 
     
T: prophylactic or therapeutic trimethoprim-sulfamethoxazole 
    Antibiotics  
    Antacids  
Psychiatric disorders 
 
Up to 60% Insomnia 
Mood disorders 
Psychosis 
P: stay below 40mg/d prednisone (equivalent) 
 
T: neuroleptics, sedatives 
 
Legend to Table 2: P, prophylaxis; T, therapy 
1upon prolonged use  
